GLP-1 agonists that have beneficial effects on glycemic control, weight gain and blood pressure in type 2 diabetes should continue to be considered for clinical trials in PCOS to assess their ability to chronically improve the multiple manifestations of the syndrome. Here, GLP1R is linked to type 2 diabetes mellitus.